ArticleDiabetes care2012
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes.
Article in Diabetes care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval.Diabetes · 2025Trial
- The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.Diabetes · 2021Trial
- C-Peptide Provides Critical Contextual Insight Into Elevated Glucose Values During Progression to Type 1 Diabetes.Diabetes care · 2026Review
- Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function.The Journal of clinical endocrinology and metabolism · 2025Article
- Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study.Diabetes care · 2025Article
- IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes.Diabetologia · 2025Article
- Type 1 Diabetes: A Disorder of the Exocrine and Endocrine Pancreas.Journal of cellular immunology · 2023Article
- Rising Hemoglobin A1c in the Nondiabetic Range Predicts Progression of Type 1 Diabetes As Well As Oral Glucose Tolerance Tests.Diabetes care · 2022Article
- Continuous Glucose Monitoring Profiles in Healthy, Nondiabetic Young Children.Journal of the Endocrine Society · 2022Article
- Continuous Glucose Monitoring Predicts Progression to Diabetes in Autoantibody Positive Children.The Journal of clinical endocrinology and metabolism · 2019Article
- Biomarkers of islet beta cell stress and death in type 1 diabetes.Diabetologia · 2018Review
- The Effect of Age on the Progression and Severity of Type 1 Diabetes: Potential Effects on Disease Mechanisms.Current diabetes reports · 2018Review
- Predicting progression to diabetes in islet autoantibody positive children.Journal of autoimmunity · 2018Article
- Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?Diabetes care · 2016Article
- Staging the progression to type 1 diabetes with prediagnostic markers.Current opinion in endocrinology, diabetes, and obesity · 2016Review
- Predictors of slow progression to diabetes in children with multiple islet autoantibodies.Journal of autoimmunity · 2016Article
- ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study.Diabetes technology & therapeutics · 2016Article
- Article
- OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis.Diabetologia · 2015Article
- The development, validation, and utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS).Current diabetes reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveWe assessed the utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for identifying individuals who are highly likely to progress to type 1 diabetes (T1D) within 2 years. RESEARCH DESIGN AND
methodsThe DPTRS was previously developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and was subsequently validated in the TrialNet Natural History Study (TNNHS). DPTRS components included C-peptide and glucose indexes from oral glucose tolerance testing, along with age and BMI. The cumulative incidence of T1D was determined after DPTRS thresholds were first exceeded and after the first occurrences of glucose abnormalities.
resultsThe 2-year risks after the 9.00 DPTRS threshold was exceeded were 0.88 and 0.77 in DPT-1 (n = 90) and the TNNHS (n = 69), respectively. In DPT-1, the 2-year risks were much lower after dysglycemia first occurred (0.37; n = 306) and after a 2-h glucose value between 190 and 199 mg/dL was first reached (0.64; n = 59). Among those who developed T1D in DPT-1, the 9.00 threshold was exceeded 0.81 ± 0.53 years prior to the conventional diagnosis. Postchallenge C-peptide levels were substantially higher (P = 0.001 for 30 min; P < 0.001 for other time points) when the 9.00 threshold was first exceeded compared with the levels at diagnosis.
conclusionsA DPTRS threshold of 9.00 identifies individuals who are very highly likely to progress to the conventional diagnosis of T1D within 2 years and, thus, are essentially in a preclinical diabetic state. The 9.00 threshold is exceeded well before diagnosis, when stimulated C-peptide levels are substantially higher.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.